Back to News
Market Impact: 0.2
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
Source: GlobeNewswire
Healthcare & Biotech
Data showed improvement in an objective measure of impaired eye movement associated with Parkinson’s disease. Reductions in LRRK2 cerebrospinal fluid biomarkers were correlated with changes in oculomotor function and synaptic biomarkers; the report provides no numerical effect sizes or broader trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Profound Medical stock surges 20% on raised Q3 revenue outlook
- Halozyme stock rises after winning injunction against Merck
- Medical device maker Centinel Spine discloses revenue rise in US IPO filing
- BTIG cuts ArriVent BioPharma stock price target on trial results
- MustGrow Biologics at 20th iif: sales grow as Bayer backs pipeline
- Healthcare Services Group acquires NEXDINE Hospitality for $93.5M
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Live Event Center, In-App Documents, and Faster Transcripts
- How to Automate Equity Research Workflows: A Control-First Guide